Drug-induced anaphylaxis: A decade review of reporting to the Portuguese Pharmacovigilance Authority

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 673-681

  Ribeiro Vaz, Inês ^a   Marques, Joana ^a   Demoly, Pascal ^b,c   Polónia, Jorge ^a   Gomes, Eva Rebelo ^d  

^a University of Porto   (Portugal)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d Institute of Biomedical Sciences Abel Salazar   (Portugal)

Author keywords

Adverse drug reaction reporting system; Anaphylaxis; Drug induced anaphylaxis; Pharmacovigilance

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIPARKINSON AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT; BRONCHODILATING AGENT; CONTRAST MEDIUM; CYTOTOXIC AGENT; DERMATOLOGICAL AGENT; EXPECTORANT AGENT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INSULIN; LOCAL ANESTHETIC AGENT; NEUROMUSCULAR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLASMA SUBSTITUTE; SEX HORMONE; SPASMOLYTIC AGENT; UNINDEXED DRUG; VACCINE; VASODILATOR AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANAPHYLAXIS; ARTICLE; CHILD; DISEASE SEVERITY; DRUG FATALITY; DRUG MANUFACTURE; DRUG SURVEILLANCE PROGRAM; FEMALE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PORTUGAL; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; AGED; AGED, 80 AND OVER; ANAPHYLAXIS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; DRUG THERAPY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHARMACOVIGILANCE; PORTUGAL; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84877111348     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1376-5     Document Type: Article

References (45)

1. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF et al (2004) Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immun 113(5):832-836
2. Aronson JK, Ferner RE (2003) Joining the DoTS: new approach to classifying adverse drug reactions. Br Med J 327:1222-1225
3. Haque RA, Wagner A, Whisken JA, Nasser SM, Ewan PW (2010) Anaphylaxis to patent blue V: a case series and proposed diagnostic protocol. Allergy 65(3):396-400
4. Mulla ZD, Ebrahim MS, Gonzalez JL (2010) Anaphylaxis in the obstetric patient: analysis of a statewide hospital discharge database. Ann Allergy Asthma Immunol 104(1):55-59
5. International Collaborative Study of Severe Anaphylaxis (2003) Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Saf12(3):195-202
6. Botsis T, Ball R (2011) Network analysis of possible anaphylaxis cases reported to the US vaccine adverse event reporting system after H1N1 influenza vaccine. Stud Health Technol Inf 169:564-568
7. Van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH (1993) A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol 35(4):400-408
8. Marguet C, Couderc L, Blanc T, Amar R, Leloet C, Feray D et al (1999) Anaphylaxis in children and adolescents: apropos of 44 patients aged 2 months to 15 years. Arch Pediatr 6[Suppl 1]:72S-78S
9. Techapornroong M, Akrawinthawong K, Cheungpasitporni W, Ruxrungtham K (2010) Anaphylaxis: a ten years inpatient retrospective study. Asian Pac J Allergy Immunol 28(4):262-269
10. VanDerKlauw MM, Wilson JHP, Stricker BHC (1996) Drug-associated anaphylaxis: 20 years of reporting in the Netherlands (1974-1994) and review of the literature. Clin Exp Allergy 26(12):1355-1363
11. Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A et al (2006) Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117(2):391-397
12. Ministry of Health (2004) Order no. 21844/2004
13. World Health Organization (2011). The Uppsala Monitoring Centre, Uppsala. Available at: http://www.who-umc.org/. Accessed 9 Feb 2011
14. Decker WW, Campbell RL, Manivannan V, Luke A, St Sauver JL, Weaver A et al (2008) The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 122(6):1161-1165
15. Gupta R, Sheikh A, Strachan DP, Anderson HR (2007) Time trends in allergic disorders in the UK. Thorax 62(1):91-96
16. Tang ML, Osborne N, Allen K (2009) Epidemiology of anaphylaxis. Curr Opin Allergy Clin Immunol 9(4):351-356
17. Sheikh A, Alves B (2000) Hospital admissions for acute anaphylaxis: time trend study. Br Med J 320(7247):1441
18. Liew WK, Williamson E, Tang ML (2009) Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 123(2):434-442
19. Gonzalez-Perez A, Aponte Z, Vidaurre CF, Rodriguez LA (2010) Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. J Allergy Clin Immunol 125(5):1098-1104 e1
20. Backstrom M, Mjorndal T, Dahlqvist R (2004) Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 13(7):483-487
21. Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ (2006) Influence of pharmacists' attitudes on adverse drug reaction reporting - A case-control study in Portugal. Drug Saf 29(4):331-340
22. Cullen DJ, Bates DW, Small SD, Cooper JB, Nemeskal AR, Leape LL (1995) The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv 21(10):541-548
23. Le J, Nguyen T, Law AV, Hodding J (2006) Adverse drug reactions among children over a 10-year period. Pediatrics 118(2):555-262
24. Jha AK, Kuperman GJ, Teich JM, Leape L, Shea B, Rittenberg E et al (1998) Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 5(3):305-314
25. Mittmann N, Knowles SR, Gomez M, Fish JS, Cartotto R, Shear NH (2004) Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf 27(7):477-487
26. Mertes PM, Alla F, Trechot P, Auroy Y, Jougla E (2011) Anaphylaxis during anesthesia in France: an 8-year national survey. J Allergy Clin Immunol 128(2):366-373
27. Thong BY, Tan TC (2011) Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 71(5):684-700
28. Star K, Noren GN, Nordin K, Edwards IR (2011) Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase. Drug Saf 34(5):415-428
29. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM, Thompson RS (2004) Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol 113(3):536-542
30. Simons FE, Peterson S, Black CD (2002) Epinephrine dispensing patterns for an out-of-hospital population: a novel approach to studying the epidemiology of anaphylaxis. J Allergy Clin Immunol 110(4):647-651
31. Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ (1999) A prospective study of adverse drug reactions in hospitalized children. Br J Clin Pharmacol 47(6):681-688
32. Benahmed S, Picot MC, Hillaire-Buys D, Blayac JP, Dujols P, Demoly P (2005) Comparison of pharmacovigilance algorithms in drug hypersensitivity reactions. Eur J Clin Pharmacol 61(7):537-541
33. Benahmed S, Picot MC, Dumas F, Demoly P (2005) Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch Intern Med 165(13):1500-1505
34. Low I, Stables S (2006) Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005. Pathology 38(4):328-332
35. Pumphrey R (2004) Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 4(4):285-290
36. Pumphrey RS (2000) Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 30(8):1144-1150
37. Pumphrey RS (2004) Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp 257:116-228, discussion 28-32, 57-60, 276-285
38. de Silva IL, Mehr SS, Tey D, Tang ML (2008) Paediatric anaphylaxis: a 5 year retrospective review. Allergy 63(8):1071-1076
39. Braganza SC, Acworth JP, McKinnon DR, Peake JE, Brown AF (2006) Paediatric emergency department anaphylaxis: different patterns from adults. Arch Dis Child 91(2):159-163
40. Alves B, Sheikh A (2001) Age specific aetiology of anaphylaxis. Arch Dis Child 85(4):348
41. Kimland E, Rane A, Ufer M, Panagiotidis G (2005) Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf 14(7):493-499
42. Aagaard L, Weber CB, Hansen EH (2010) Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf 33(4):327-339
43. Hawcutt DB, Mainie P, Riordan A, Smyth RL, Pirmohamed M (2012) Reported paediatric adverse drug reactions in the UK 2000-2009. Br J Clin Pharmacol 73(3):437-446
44. Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29(5):385-396
45. Erlewyn-Lajeunesse M, Dymond S, Slade I, Mansfield HL, Fish R, Jones O et al (2010) Diagnostic utility of two case definitions for anaphylaxis: a comparison using a retrospective case notes analysis in the UK. Drug Saf 33(1):57-64